misoprostol use in obstetrics and gynaecology
TRANSCRIPT
![Page 1: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/1.jpg)
MISOPROSTOL USE IN OBSTETRICS AND GYNAECOLOGY
DR OBIOKONKWO, A.C.[MBBS, U. PHARCOURT]
DEPARTMENT OF OBSTETRICS AND GYNAECOLOGYFEDERAL MEDICAL CENTRE BIRNIN KEBBI
KEBBI STATE
![Page 2: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/2.jpg)
05/03/23 facebook.com/imezi2
Outline
Introduction Pharmacology Uses in obstetrics and gynaecology Other uses Controversies Conclusion & Recommendations References
![Page 3: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/3.jpg)
05/03/23 facebook.com/imezi3
Introduction
Drug use is almost as old as man. Records - Sumerians use dating as far back as 5000 B.C. [1]
Some drugs were found to be harmful, but others found to be extremely useful
Misoprostol belongs to the useful group and in 2011, was added to the WHO model list of essential medicines
![Page 4: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/4.jpg)
05/03/23 facebook.com/imezi4
Introduction
Developed by G.D. Searle & Company in 1973
Originally approved by the Food and Drug Administration (FDA) for the prevention of stomach ulcers in patients taking nonsteroidal anti-inflammatory drugs
Currently used for a variety on on- and off-label indications
![Page 5: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/5.jpg)
05/03/23 facebook.com/imezi5
Pharmacology [2]
Synthetic analogue of prostaglandin E1 (PgE1)
Formular – C22H38O5 ; molar mass – 382.534 g/mol
Routes of admin - oral, vaginal, sublingual, buccal, rectal
Extensively absorbed, 80 – 90% protein bound
Metabolized in the liver, excreted in urine (80%)
Elimination half life 20 – 40 minutes
![Page 6: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/6.jpg)
05/03/23 facebook.com/imezi6
Pharmacology [2]
15-deoxy-16-hydroxy-16-methyl-PgE1
![Page 7: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/7.jpg)
05/03/23 facebook.com/imezi7
Pharmacology [2]
Cheap and heat-stable, able to stimulate uterine contractility in early pregnancy & at term
There are no known drug interactions with misoprostol [3]
Pregnancy category X
![Page 8: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/8.jpg)
05/03/23 facebook.com/imezi8
Pharmacology [2]
It is considered a teratogen. [3] Absolute risk – 1%
Congenital malformations thought to be due to vascular disruptions secondary to uterine contractions caused by misoprostol
Defects: skull defects, bladder extrophy, arthrogryposis, CN palsies, facial malformations, limb defects, Moebius sequence
![Page 9: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/9.jpg)
05/03/23 facebook.com/imezi9
Pharmacology [2]
Adverse effects...
Uterine hyperstimulation
Hyperthermia
Chills
Vaginal bleeding
![Page 10: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/10.jpg)
05/03/23 facebook.com/imezi10
Pharmacology [2]
...Adverse effects
Diarrhoea
Abdominal pain
Clinical exacerbation of inflammatory bowel disease
Anaphylaxis
![Page 11: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/11.jpg)
05/03/23 facebook.com/imezi11
Use in Obstetrics and Gynaecology
Obstetric uses Cervical ripening and induction of labour (IOL) Post partum haemorrhage (PPH)
Gynaecological uses Termination of pregnancy (medically) Cervical ripening before instrumentation
![Page 12: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/12.jpg)
05/03/23 facebook.com/imezi12
Cervical ripening and induction of labour
Low dose oral misoprostol (20-25µg 2-hourly) is safer and more effective than vaginal misoprostol [4]
Vaginal misoprostol in doses >25µg 4-hourly is associated with a greater risk of uterine hyperstimulation [4]
![Page 13: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/13.jpg)
05/03/23 facebook.com/imezi13
Cervical ripening and induction of labour
Misoprostol vs placebo...
10 trials [4] involving 1141 women
Vaginal misoprostol – less failure to deliver within 24 hours
Uterine hyperstimulation without foetal heart changes was increased
![Page 14: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/14.jpg)
05/03/23 facebook.com/imezi14
Cervical ripening and induction of labour
...Misoprostol vs placebo
Oral misoprostol - more likely to deliver in 24 hours, less need for oxytocin use, lower caesarean delivery rate
![Page 15: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/15.jpg)
05/03/23 facebook.com/imezi15
Cervical ripening and induction of labour
Misoprostol vs oxytocin...
25 trials [4] involving 3074 participants
Vaginal misoprostol more effective than oxytocin for IOL
Use of less than 50µg misoprostol showed no reduction in failure to deliver within 24 hours
![Page 16: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/16.jpg)
05/03/23 facebook.com/imezi16
Cervical ripening and induction of labour
...Misoprostol vs oxytocin
Uterine hyperstimulation without foetal heart changes commoner in the misoprostol group
No difference in perinatal or maternal adverse outcome between groups
Increase in meconium-stained liquor in oral misoprostol vs intravenous oxytocin
![Page 17: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/17.jpg)
05/03/23 facebook.com/imezi17
Cervical ripening and induction of labour
Misoprostol vs other prostaglandins (especially dinoprostone)...
38 trials,[4] 7022 participants
Failure to deliver vaginally within 24 hours less in misoprostol group
Uterine hyperstimulation with FHR changes and meconium-stained liquor more with misoprostol
![Page 18: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/18.jpg)
05/03/23 facebook.com/imezi18
Cervical ripening and induction of labour
...Misoprostol vs other prostaglandins
Oral misoprostol less likely than vaginal dinoprostone have a caesarean delivery
Oral misoprostol group less likely to deliver within 24 hours vs vaginal dinoprostone
![Page 19: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/19.jpg)
05/03/23 facebook.com/imezi19
Cervical ripening and induction of labour
Recommended dosing [5]
Intravaginally, 25µg 6-hourly or
Orally, 25µg 2-hourly
Contraindicated in women with a previous uterine scar
![Page 20: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/20.jpg)
05/03/23 facebook.com/imezi20
Safe single doses of vaginal misoprostol for producing uterine contractions at various
gestations
![Page 21: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/21.jpg)
05/03/23 facebook.com/imezi21
Post-partum haemorrhage
Useful for both the prevention and treatment of PPH
For treatment, evidence[6] shows that...
Oral route of admin fast uptake, but shortest duration of action
![Page 22: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/22.jpg)
05/03/23 facebook.com/imezi22
Post-partum haemorrhage
...For treatment, evidence[6] shows that
Rectal route has slow uptake with a prolonged duration of action
Buccal and sublingual routes have rapid uptake, prolonged duration of action and greatest total bioavailability
![Page 23: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/23.jpg)
05/03/23 facebook.com/imezi23
Post-partum haemorrhage
PPH prophylaxis [7]
Oral dose of 600µg stat Not as effective as oxytocin Exclude second twin before administration
PPH treatment [8]
Sublingual dose of 800µg stat
![Page 24: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/24.jpg)
05/03/23 facebook.com/imezi24
Termination of pregnancy
First trimester medical abortion...
Indicated for induced, missed or incomplete abortion
FDA-approved regimen can be initiated up to 49 days from 1st day of last menstrual period
Involves use of misoprostol alone or in combination with mifepristone or methotrexate
![Page 25: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/25.jpg)
05/03/23 facebook.com/imezi25
Termination of pregnancy
...First trimester medical abortion
Mifepristone, 600µg PO stat + misoprostol, 400µg PO on day 3
Methotrexate, 50 mg/m2 IM + misoprostol 800µg PV on day 5
![Page 26: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/26.jpg)
05/03/23 facebook.com/imezi26
Termination of pregnancy
Second trimester... [9]
Indicated for IUFD and congenital anomalies incompatible with life
Vaginal misoprostol more effective than oral misoprostol [10] in T2 and T3
Also as effective as the traditionally used gemeprost
IUFD:13-17 weeks, 200µg 6-hourly vaginally x4 max
![Page 27: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/27.jpg)
05/03/23 facebook.com/imezi27
Termination of pregnancy
...Second trimester [9]
18-26 weeks. 100µg 6-hourly vaginally, x4 max
Interruption of pregnancy: 400µg vaginally or sublingually 3-hourly x5 max
Caution in women with uterine scars
![Page 28: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/28.jpg)
05/03/23 facebook.com/imezi28
Cervical ripening pre-instrumentation[9]
First trimester
Vaginally or sublingually, 400µg 3 hours prior to procedure
Indications Insertion of IUD Surgical termination of pregnancy Hysteroscopy
![Page 29: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/29.jpg)
05/03/23 facebook.com/imezi29
Other uses
Currently ONLY approved by the Food and Drug Administration (FDA) for prevention of gastric ulcers resulting from chronic administration of non-steroidal anti-inflammatory drugs eg in the elderly
![Page 30: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/30.jpg)
05/03/23 facebook.com/imezi30
Known issues in our environment...
Difficulty in compounding recommended dose
Easy access to misoprostol by health and non-health workers
Self administration by some at home for self induction of labour or abortions
![Page 31: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/31.jpg)
05/03/23 facebook.com/imezi31
...Known issues in our environment
The small chance of developing Moebius syndrome in failed misoprostol-induced abortion
![Page 32: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/32.jpg)
05/03/23 facebook.com/imezi32
Controversies
Manufacturers of Cytotec™ issued letters in 2000 warning against use of misoprostol in pregnant women
Safety of misoprostol versus other agents used for IOL
Political tussle of pro- versus anti-abortion hardliners
Mifepristone versus misoprostol for TOP
![Page 33: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/33.jpg)
05/03/23 facebook.com/imezi33
Recommendations
Consider oral route for IOL with misoprostol
Evidence[6] shows the sublingual route to be the most promising. Consider this for treatment of PPH
Consider local compounding of oral misoprostol to easily administer the recommended dosage
![Page 34: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/34.jpg)
05/03/23 facebook.com/imezi34
Conclusion
The discovery of misoprostol could easily be regarded as one of the best things in modern medicine secondary to antibiotics
Though the use in ObGyn is off-label, it's legal and have been highly recommended by several authorities
Misoprostol use in obstetrics is a double-edged sword – our duty
![Page 35: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/35.jpg)
05/03/23 facebook.com/imezi35
THANK YOU FOR LISTENING!
![Page 36: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/36.jpg)
05/03/23 facebook.com/imezi36
References
1. The Schaffer Library of Drug Policy: A summary of Historical events. Available from http://www.druglibrary.org/schaffer/history/histsum.htm
2. Hoogerwerf WA, Pasricha JP. Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. Chicago: McGraw-Hill; 2006
3. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001; 334:38-47
4. Abdel-Aleem H. Misoprostol for cervical ripening and induction of labour: RHL commentary (last revised: 1 May 2011). The WHO Reproductive Health Library; Geneva: World Health Organization.
5. WHO recommendations for induction of labour, 2011. Retrieved from http://www.misoprostol.org/dosage-guidelines/
![Page 37: Misoprostol use in Obstetrics and Gynaecology](https://reader035.vdocuments.mx/reader035/viewer/2022070601/588205b21a28abf05e8b5877/html5/thumbnails/37.jpg)
05/03/23 facebook.com/imezi37
References
6. Hofmeyr GJ, Walraven G, Gulmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG 2005; 112: 547-53 doi: 10.1111/j.1471-0528.2004.00512.x pmid: 15842275.
7. FIGO Guidelines: Prevention of PPH with misoprostol, 2012. Retrieved from http://www.misoprostol.org/dosage-guidelines/
8. FIGO Guidelines: Treatment of PPH with misoprostol, 2012. Retrieved from http://www.misoprostol.org/dosage-guidelines/
9. WHO/RHR. Safe abortion: technical and policy guidelines for health systems (2nd edition), 2012. Retrieved from http://www.misoprostol.org/dosage-guidelines/
10. Matthews JE. Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine foetal death: RHL commentary (last revised: 1 October 2010). The WHO Reprobuctive Health Library; Geneva: World Health Organization.